1. Blondeau JM, Laskowski R, Bjarnason J, et al. Comparative in vitro activity of gatifloxacin, grepafloxacin, levofloxacin, moxifloxacin and trovafloxacin against 4151 Gram-negative and Gram-positive organisms. Int J Antimicrob Agents. 2000;14:45–50.
2. Huczko E, Conetta B, Bonner D, et al. Susceptibility of bacterial isolates to gatifloxacin and ciprofloxacin from clinical trials 1997-1998. Int J Antimicrob Agents. 2000;16:401–405.
3. Fukuda H, Kishii R, Takei M, et al. Contributions of the 8-methoxy group of
gatifloxacin to resistance selectivity, target preference, and antibacterial activity against Streptococcus pneumoniae. Antimicrob Agents Chemother. 2001;45:1649–1653.
4. Ince D, Hooper DC. Mechanisms and frequency of resistance to atifloxacin in comparison to AM-1121 and ciprofloxacin in Staphylococcus aureus. Antimicrob Agents Chemother. 2001;45:2755–2764.
5. Drlica K. Mechanism of fluoroquinolone action. Curr Opin Microbiol. 1999;2:504–508.
6. Takei M, Fukuda H, Yasue T, et al. Inhibitory activities of gatifloxacin (AM-1155), a newly developed fluoroquinolone, against bacterial and mammalian type II topoisomerases. Antimicrob Agents Chemother. 1998;42:2678–2681.
Zymar as an Ocular Therapeutic Agent ’ 81